EMPHASIS-HF Mortality Reduction Index

Clinical calculation support · Verify results before clinical use

Patient profile

Masukkan parameter klinis untuk melihat ilustrasi kalkulasi. Ini bukan model prognostik tervalidasi.

HFHFrEF
Rentang input: 18–120 tahun.
Trial EMPHASIS-HF terutama merekrut pasien NYHA kelas II.
Kalium penting untuk keamanan mineralocorticoid receptor antagonist.

Clinical context

EMPHASIS-HF evaluated eplerenone added to recommended therapy in patients with chronic systolic heart failure and mild symptoms. The primary endpoint was cardiovascular death or hospitalization for heart failure.

Key trial findings

OutcomeEplerenonePlaceboEffect
Primary composite endpoint18.3%25.9%HR 0.63 (95% CI 0.54–0.74)
Death from any cause12.5%15.5%HR 0.76 (95% CI 0.62–0.93)
Death from cardiovascular causes10.8%13.5%HR 0.76 (95% CI 0.61–0.94)

Safety considerations

EMPHASIS-HF reported serum potassium above 5.5 mmol/L in 11.8% of participants receiving eplerenone and 7.2% receiving placebo. Assess renal function and potassium, and follow current prescribing information and applicable heart-failure guidance when treating patients.

References

Zannad F, McMurray JJV, Krum H, et al.Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med. 2011;364:11–21. doi:10.1056/NEJMoa1009492
EMPHASIS-HF Study GroupClinicalTrials.gov registration: NCT00232180. Trial population and endpoints should be considered when applying these findings.
Clinical disclaimer: Tool ini bersifat edukasional. Model personalisasi dalam kalkulator belum divalidasi eksternal dan tidak menggantikan clinical judgement, penilaian kelayakan MRA, pemeriksaan fungsi ginjal/kalium, atau rekomendasi guideline. Jangan gunakan estimasi risiko atau NNT ilustratif untuk keputusan klinis pasien.